查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1300974

血栓和止血生物标誌物市场规模、份额和趋势分析报告：按产品、按测试地点、按测试类型、按应用、按最终用途、按地区、细分市场预测，2023-2030 年

Thrombosis And Hemostasis Biomarkers Market Size, Share & Trends Analysis Report By Product (Analyzers, Reagents & Consumables), By Test Location, By Test Type, By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10个工作天内

价格

血栓和止血生物标誌物市场增长和趋势

全球血栓和止血生物标誌物市场规模预计2023年至2030年復合年增长率为5.90%，2030年达到79.2亿美元。

市场的快速增长归因于胰腺癌等慢性病患病率的增加、人口老龄化的加剧、个性化药物需求的增加以及技术进步等因素。

由于采用模式的变化和新技术的引入，血栓和止血生物标誌物行业近年来显着增长。 市场上 POC 分析仪日益普及的趋势是紧凑型分析仪的驱动力。 对小型和超小型设备的研究预计将继续增加。 例如，2022年6月，Arnold Lining Ju博士宣布开发出一种微型设备，可以检测血栓，可用于检测心脏病发作的早期迹象。

深静脉血栓 (DVT)、肺栓塞 (PE) 和胰腺癌等慢性疾病的流行预计将增加对血栓止血生物标誌物的需求，以检测止血潜力。 慢性疾病往往会损害血管，导致形成血栓，限制血液流动，并可能导致中风和心脏病等严重的健康并发症。 例如，肺栓塞 (PE) 是一种严重的疾病，从腿部开始并传播到肺部以阻止血液流动。

据美国肺臟协会称，2023年1月，美国将有近90万人发生肺栓塞，并且约33%的曾发生肺栓塞的人将在10年内再次发生肺栓塞的报导。 因此，病例的高患病率和高重复率导致对血栓和止血生物标誌物的需求增加。

此外，市场上的主要参与者正在专注于併购等各种形式的战略举措，以增强各自在血栓和止血生物标誌物行业的地位。 例如，2023 年 1 月，赛默飞世尔科技宣布与阿斯利康合作生产 Tagrisso 的血液和实体组织伴随诊断测试。 预计这将推动血栓和止血生物标誌物行业的发展。 此外，2022 年 5 月，Quidel Corporation 以 60 亿美元收购了 Ortho Clinical Diagnostics。 新公司名为 QuidelOrtho。 此次收购使 Quidel 能够获得 Ortho Clinical Diagnostics 的生物标誌物测试组合。

血栓止血生物标誌物市场报告亮点

  • 由于全球人口出血和凝血疾病的患病率不断上升，试剂和耗材市场在 2022 年占据了最大的销售份额。
  • 临床诊断将在 2022 年推动整个市场的发展，因为它们可以在处理大量样本的同时诊断和识别凝血过程中的异常情况。
  • 由于可以监测抗凝功效的测试质量，凝血□后 (PT) 测试在 2022 年的销售额中占据最大份额。
  • 由于深静脉血栓 (DVT) 的高患病率和高死亡风险，其在 2022 年的销售额中所占份额最大。
  • 诊断中心在 2022 年的销售额中占据最大份额，因为医院越来越依赖诊断中心进行检测，并且需要专用设备来提供更快的检测结果。存在是不同的。
  • 由于血栓性疾病的高发病率和先进技术的普及，北美在 2022 年占据了市场主导地位。
  • 主要市场参与者包括 BioMerieux SA、Abbott、Werfen、HORIBA Ltd.、Quidel Corporation、F. Hoffmann-La Roche Ltd.、Diazyme Laboratories, Inc.、Biomedica Diagnostics、Thermo Fisher Scientific, Inc.、Siemens Healthineers 等。

内容

第一章调查方法及范围

  • 市场细分和范围
  • 区域范围
  • 估计/预测时间表
  • 目的
  • 调查方法
  • 信息获取
  • 信息或数据分析
  • 市场形成和验证
  • 型号详细信息
  • 辅助信息列表
  • 缩写列表

第 2 章执行摘要

第 3 章血栓止血生物标誌物市场变量、趋势和范围

  • 血栓和止血生物标誌物市场谱系展望
    • 母公司市场前景
    • 辅助市场
  • 市场动态
    • 市场驱动因素分析
    • 市场製约因素分析
  • 血栓止血生物标誌物市场分析工具
    • 波特五力分析
    • 杵分析

第 4 章血栓和止血生物标誌物市场细分分析（按产品），2018-2030 年

  • 血栓和止血生物标誌物市场：产品变异分析
  • 按产品
    • 分析器
    • 试剂和消耗品

第 5 章血栓和止血生物标誌物市场 - 细分分析（按地点），2018-2030 年

  • 血栓和止血生物标誌物市场：测试地点的变化分析
  • 按检查地点
    • 实验室测试
    • 即时检测

第 6 章血栓和止血生物标誌物市场 - 细分分析（按测试类型），2018-2030

  • 血栓和止血生物标誌物市场：测试类型的变异分析
  • 按测试类型
    • D-二聚体
    • 抗凝血□ III
    • 纤溶□原
    • 纤维蛋白/纤维蛋白原
    • 可溶性纤维蛋白
    • 选择素
    • 因素 8
    • 点
    • 适合
    • 其他

第 7 章血栓和止血生物标记物市场细分分析（按应用），2018-2030

  • 血栓和止血生物标誌物市场：应用变化分析
  • 按用途
    • 深静脉血栓形成 (Dvt)
    • 肺栓塞 (Pe)
    • 弥散性血管内凝血 (Dic)
    • 其他

第 8 章血栓和止血生物标誌物市场 - 细分分析，按最终用途，2018-2030 年

  • 血栓和止血生物标誌物市场：最终用途的变化分析
  • 按最终用途
    • 医院和诊所
    • 学术研究机构
    • 诊断中心
    • 其他

第 9 章血栓和止血生物标誌物市场：按地区、分产品、测试地点、测试类型、应用和最终用途进行估算和趋势分析

  • 血栓市场：区域展望
  • 北美
    • 2018-2030 年北美血栓和止血生物标誌物市场估计和预测
    • 美国
    • 加拿大
  • 欧洲
    • 2018-2030 年欧洲血栓和止血生物标誌物市场估计和预测
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 意大利
    • 丹麦
    • 瑞典
    • 挪威
    • 欧洲其他地区
  • 亚太地区
    • 2018-2030 年亚太地区血栓和止血生物标誌物市场估算和预测
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳大利亚
    • 泰国
    • 亚太地区其他地区
  • 拉丁美洲
    • 2018-2030 年拉丁美洲血栓和止血生物标誌物市场估计和预测
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他拉丁美洲地区
  • MEA
    • 2018-2030 年 MEA 血栓和止血生物标誌物市场估算和预测
    • 南非
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 科威特
    • 其他中东/非洲

第 10 章竞争格局

  • 公司分类
  • 战略规划
    • 推出新产品
    • 合作伙伴关係
    • 获取
    • 合作
    • 筹款
  • 2022 年主要参与者的市场份额分析
  • 公司简介
    • Thermo Fisher Scientific, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Siemens Healthineers
    • Abbott
    • BioMerieux SA
    • Werfen
    • HORIBA Ltd.
    • Quidel Corporation
    • Diazyme Laboratories, Inc.
    • Biomedica Diagnostics

第11章 结论

Product Code: GVR-4-68040-081-8

Thrombosis And Hemostasis Biomarkers Market Growth & Trends

The global thrombosis and hemostasis biomarkers market size is expected to reach USD 7.92 Billion by 2030, expanding at a CAGR of 5.90% from 2023 to 2030. The rapid growth of the market is attributable to factors such as the increasing prevalence of chronic diseases such as pancreatic cancer, the rise in the geriatric population, the growing demand for personalized medicines, and advancements in technology.

The thrombosis & hemostasis biomarkers industry has grown significantly in recent years, with changes in adoption patterns and the introduction of novel technologies. The increasing trend of adopting POC analyzers in the market is creating traction for small-sized analyzers. Increasing research on mini- and microdevices is anticipated to continue over the coming years. For instance, in June 2022, Dr. Arnold Lining Ju announced the development of a microdevice that can detect blood clots and can be used to detect early signs of a heart attack.

The prevalence of chronic diseases such as deep vein thrombosis (DVT), pulmonary embolism (PE), and pancreatic cancer is anticipated drive the need for thrombosis & hemostasis biomarkers to detect the probability of hemostasis. Chronic diseases have a tendency to damage blood vessels, leading to the formation of clots that can block blood flow and cause serious health complications, such as stroke & heart attack. For instance, pulmonary embolism (PE), is a serious medical condition that occurs in the legs and travels to the lung, obstructing blood flow.

As per American Lung Association, in January 2023, PE affected nearly 900,000 people in the U.S. and nearly 33% of the people affected by (DVT) or pulmonary embolism (PE) experience recurrence of PE in ten years. Therefore, high prevalence and significant repetition of cases will lead to an increase in the demand for thrombosis & hemostasis biomarkers.

Furthermore, key players operating in the market are focusing on different forms of strategic initiatives such as mergers and acquisitions to increase their respective position in the thrombosis & hemostasis biomarkers industry. For instance, in January 2023, Thermo Fisher Scientific, Inc., announced a partnership with AstraZeneca to manufacture a blood-based and solid tissue companion diagnostic test for Tagrisso. This was expected to propel the thrombosis and hemostasis biomarkers industry. Additionally, in May 2022, Quidel Corporation acquired Ortho Clinical Diagnostics for USD 6 billion. The new company was named QuidelOrtho. Through this acquisition, Quidel gained access to Ortho Clinical Diagnostics' biomarker tests portfolio.

Thrombosis And Hemostasis Biomarkers Market Report Highlights

  • Reagents and consumables segment of the market held the largest revenue share in 2022 and is attributable to the heightened prevalence of bleeding and coagulation disorders in the global population
  • Clinical laboratory tests led the overall market in 2022, owing to their ability to diagnose and identify abnormalities in the blood clotting process while processing a high volume of samples
  • Post-thrombin (PT) test held the largest revenue share in 2022, attributable to the test quality which allows monitoring the effectiveness of anticoagulant medications
  • Deep Vein Thrombosis (DVT) held the largest revenue share in 2022, owing to its high prevalence and the high mortality risk
  • Diagnostic centers held the largest revenue share in 2022, attributable to the growing reliance of hospitals on diagnostic centers for testing and the presence of specialized equipment to provide faster test results
  • North America dominated the market in 2022 which can be attributed to a significant prevalence of thrombosis and hemostasis disorders, along with access to advanced technology
  • A few of the key market playersinclude bioMerieux SA; Abbott; Werfen; HORIBA Ltd.; Quidel Corporation; F. Hoffmann-La Roche Ltd.; Diazyme Laboratories, Inc.; Biomedica Diagnostics; Thermo Fisher Scientific, Inc.; Siemens Healthineers.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment Definitions
      • 1.1.1.1 Product Segment
      • 1.1.1.2 Test Location Segment
      • 1.1.1.3 Test Type Segment
      • 1.1.1.4 Application Segment
      • 1.1.1.5 End-Use Segment
  • 1.2 Regional Scope
  • 1.3 Estimates And Forecast Timeline
  • 1.4 Objectives
    • 1.4.1 Objective - 1
    • 1.4.2 Objective - 2
    • 1.4.3 Objective - 3
  • 1.5 Research Methodology
  • 1.6 Information Procurement
    • 1.6.1 Purchased Database
    • 1.6.2 Gvr's Internal Database
    • 1.6.3 Secondary Sources
    • 1.6.4 Primary Research
  • 1.7 Information Or Data Analysis
    • 1.7.1 Data Analysis Models
  • 1.8 Market Formulation & Validation
  • 1.9 Model Details
    • 1.9.1 Commodity Flow Analysis
  • 1.10 List Of Secondary Sources
  • 1.11 List Of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Product And Test Location Segment Snapshot
  • 2.3 Test Type Segment Snapshot
  • 2.4 Application And End Use Segment Snapshot
  • 2.5 Competitive Landscape Snapshot

Chapter 3 Thrombosis & Hemostasis Biomarkers Market Variables, Trends, And Scope

  • 3.1 Thrombosis & Hemostasis Biomarkers Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Ancillary Market
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Analysis
      • 3.2.1.1 Increasing Prevalence Of Chronic Diseases
      • 3.2.1.1.1 Incidence Data Of Pancreatic Cancer
      • 3.2.1.2 Growing Geriatric Population
      • 3.2.1.3 Increasing Demand For Personalized Medicine
      • 3.2.1.4 Advancements In Technology
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 High Cost Of Diagnostic Tests
      • 3.2.2.2 Complexity Of Thrombotic Events
  • 3.3 Thrombosis & Hemostasis Biomarkers Market Analysis Tools
    • 3.3.1 Porter's Five Forces Analysis
    • 3.3.2 Pestle Analysis

Chapter 4 Thrombosis & Hemostasis Biomarkers Market - Segment Analysis, By Product, 2018 - 2030 (USD Million)

  • 4.1 Thrombosis & Hemostasis Biomarkers Market: Product Movement Analysis
  • 4.2 Thrombosis & Hemostasis Biomarkers Market Estimates & Forecast, By Product (USD Million)
    • 4.2.1 Analyzers
    • 4.2.2 Reagents & Consumables

Chapter 5 Thrombosis & Hemostasis Biomarkers Market - Segment Analysis, By Test Location, 2018 - 2030 (USD Million)

  • 5.1 Thrombosis & Hemostasis Biomarkers Market: Test Location Movement Analysis
  • 5.2 Thrombosis & Hemostasis Biomarkers Market Estimates & Forecast, By Test Location (USD Million)
    • 5.2.1 Clinical Laboratory Tests
    • 5.2.2 Point-Of-Care Tests

Chapter 6 Thrombosis & Hemostasis Biomarkers Market - Segment Analysis, By Test Type, 2018 - 2030 (USD Million)

  • 6.1 Thrombosis & Hemostasis Biomarkers Market: Test Type Movement Analysis
  • 6.2 Thrombosis & Hemostasis Biomarkers Market Estimates & Forecast, By Test Type (USD Million)
    • 6.2.1 D-Dimer
    • 6.2.2 Anti-Thrombin Iii
    • 6.2.3 Plasminogen
    • 6.2.4 Fibrin/Fibrinogen
    • 6.2.5 Soluble Fibrin
    • 6.2.6 Selectins
    • 6.2.7 Factor Viii
    • 6.2.8 Pt
    • 6.2.9 Aptt
    • 6.2.10 Others

Chapter 7 Thrombosis & Hemostasis Biomarkers Market - Segment Analysis, By Application, 2018 - 2030 (USD Million)

  • 7.1 Thrombosis & Hemostasis Biomarkers Market: Application Movement Analysis
  • 7.2 Thrombosis & Hemostasis Biomarkers Market Estimates & Forecast, By Application (USD Million)
    • 7.2.1 Deep Vein Thrombosis (Dvt)
    • 7.2.2 Pulmonary Embolism (Pe)
    • 7.2.3 Disseminated Intravascular Coagulation (Dic)
    • 7.2.4 Others

Chapter 8 Thrombosis & Hemostasis Biomarkers Market - Segment Analysis, By End Use, 2018 - 2030 (USD Million)

  • 8.1 Thrombosis & Hemostasis Biomarkers Market: End-Use Movement Analysis
  • 8.2 Thrombosis & Hemostasis Biomarkers Market Estimates & Forecast, By End Use (USD Million)
    • 8.2.1 Hospitals & Clinics
    • 8.2.2 Academic & Research Institute
    • 8.2.3 Diagnostic Centers
    • 8.2.4 Others

Chapter 9 Thrombosis & Hemostasis Biomarkers Market: Regional Estimates And Trend Analysis, By Product, Test Location, Test Type, Application, & End-Use

  • 9.1 Thrombosis & Hemostasis Market: Regional Outlook
  • 9.2 North America
    • 9.2.1 North America Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.2.2 U.S.
      • 9.2.2.1 Key Country Dynamics
      • 9.2.2.2 Target Disease Prevalence
      • 9.2.2.3 U.S. Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.2.2.4 Competitive Scenario
      • 9.2.2.5 Regulatory Framework
      • 9.2.2.6 Reimbursement Scenario
    • 9.2.3 Canada
      • 9.2.3.1 Key Country Dynamics
      • 9.2.3.2 Target Disease Prevalence
      • 9.2.3.3 Canada Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.2.3.4 Competitive Scenario
      • 9.2.3.5 Regulatory Framework
      • 9.2.3.6 Reimbursement Scenario
  • 9.3 Europe
    • 9.3.1 Europe Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.3.2 Uk
      • 9.3.2.1 Key Country Dynamics
      • 9.3.2.2 Target Disease Prevalence
      • 9.3.2.3 Uk Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.3.2.4 Competitive Scenario
      • 9.3.2.5 Regulatory Framework
      • 9.3.2.6 Reimbursement Scenario
    • 9.3.3 Germany
      • 9.3.3.1 Key Country Dynamics
      • 9.3.3.2 Target Disease Prevalence
      • 9.3.3.3 Germany Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.3.3.4 Competitive Scenario
      • 9.3.3.5 Regulatory Framework
      • 9.3.3.6 Reimbursement Scenario
    • 9.3.4 France
      • 9.3.4.1 Key Country Dynamics
      • 9.3.4.2 Target Disease Prevalence
      • 9.3.4.3 France Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.3.4.4 Competitive Scenario
      • 9.3.4.5 Regulatory Framework
      • 9.3.4.6 Reimbursement Scenario
    • 9.3.5 Spain
      • 9.3.5.1 Key Country Dynamics
      • 9.3.5.2 Target Disease Prevalence
      • 9.3.5.3 Spain Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.3.5.4 Competitive Scenario
      • 9.3.5.5 Regulatory Framework
      • 9.3.5.6 Reimbursement Scenario
    • 9.3.6 Italy
      • 9.3.6.1 Key Country Dynamics
      • 9.3.6.2 Target Disease Prevalence
      • 9.3.6.3 Italy Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.3.6.4 Competitive Scenario
      • 9.3.6.5 Regulatory Framework
      • 9.3.6.6 Reimbursement Scenario
    • 9.3.7 Denmark
      • 9.3.7.1 Key Country Dynamics
      • 9.3.7.2 Target Disease Prevalence
      • 9.3.7.3 Denmark Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.3.7.4 Competitive Scenario
      • 9.3.7.5 Regulatory Framework
      • 9.3.7.6 Reimbursement Scenario
    • 9.3.8 Sweden
      • 9.3.8.1 Key Country Dynamics
      • 9.3.8.2 Target Disease Prevalence
      • 9.3.8.3 Sweden Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.3.8.4 Competitive Scenario
      • 9.3.8.5 Regulatory Framework
      • 9.3.8.6 Reimbursement Scenario
    • 9.3.9 Norway
      • 9.3.9.1 Key Country Dynamics
      • 9.3.9.2 Target Disease Prevalence
      • 9.3.9.3 Norway Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.3.9.4 Competitive Scenario
      • 9.3.9.5 Regulatory Framework
      • 9.3.9.6 Reimbursement Scenario
    • 9.3.10 Rest Of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Asia Pacific Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.4.2 Japan
      • 9.4.2.1 Key Country Dynamics
      • 9.4.2.2 Death Rate In Japan
      • 9.4.2.3 Target Disease Prevalence
      • 9.4.2.4 Japan Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.4.2.5 Competitive Scenario
      • 9.4.2.6 Regulatory Framework
      • 9.4.2.7 Reimbursement Scenario
    • 9.4.3 China
      • 9.4.3.1 Key Country Dynamics
      • 9.4.3.2 Target Disease Prevalence
      • 9.4.3.3 China Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.4.3.4 Competitive Scenario
      • 9.4.3.5 Regulatory Framework
      • 9.4.3.6 Reimbursement Scenario
    • 9.4.4 India
      • 9.4.4.1 Key Country Dynamics
      • 9.4.4.2 Target Disease Prevalence
      • 9.4.4.3 India Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.4.4.4 Competitive Scenario'
      • 9.4.4.5 Regulatory Framework
      • 9.4.4.6 Reimbursement Scenario
    • 9.4.5 South Korea
      • 9.4.5.1 Key Country Dynamics
      • 9.4.5.2 Target Disease Prevalence
      • 9.4.5.3 South Korea Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.4.5.4 Competitive Scenario
      • 9.4.5.5 Regulatory Framework
      • 9.4.5.6 Reimbursement Scenario
    • 9.4.6 Australia
      • 9.4.6.1 Key Country Dynamics
      • 9.4.6.2 Target Disease Prevalence
      • 9.4.6.3 Australia Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.4.6.4 Competitive Scenario
      • 9.4.6.5 Regulatory Framework
      • 9.4.6.6 Reimbursement Scenario
    • 9.4.7 Thailand
      • 9.4.7.1 Key Country Dynamics
      • 9.4.7.2 Target Disease Prevalence
      • 9.4.7.3 Thailand Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.4.7.4 Competitive Scenario
      • 9.4.7.5 Regulatory Framework
      • 9.4.7.6 Reimbursement Scenario
    • 9.4.8 Rest Of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Latin America Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.5.2 Brazil
      • 9.5.2.1 Key Country Dynamics
      • 9.5.2.2 Brazil Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.5.2.3 Target Disease Prevalence
      • 9.5.2.4 Competitive Scenario
      • 9.5.2.5 Regulatory Framework
      • 9.5.2.6 Reimbursement Scenario
    • 9.5.3 Mexico
      • 9.5.3.1 Key Country Dynamics
      • 9.5.3.2 Target Disease Prevalence
      • 9.5.3.3 Mexico Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.5.3.4 Competitive Scenario
      • 9.5.3.5 Regulatory Framework
      • 9.5.3.6 Reimbursement Scenario
    • 9.5.4 Argentina
      • 9.5.4.1 Key Country Dynamics
      • 9.5.4.2 Target Disease Prevalence
      • 9.5.4.3 Argentina Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.5.4.4 Competitive Scenario
      • 9.5.4.5 Regulatory Framework
      • 9.5.4.6 Reimbursement Scenario
    • 9.5.5 Rest Of Latin America
  • 9.6 MEA
    • 9.6.1 MEA Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.6.2 South Africa
      • 9.6.2.1 Key Country Dynamics
      • 9.6.2.2 Target Disease Prevalence
      • 9.6.2.3 South Africa Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.6.2.4 Competitive Scenario
      • 9.6.2.5 Regulatory Framework
      • 9.6.2.6 Reimbursement Scenario
    • 9.6.3 Saudi Arabia
      • 9.6.3.1 Key Country Dynamics
      • 9.6.3.2 Target Disease Prevalence
      • 9.6.3.3 Saudi Arabia Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.6.3.4 Competitive Scenario
      • 9.6.3.5 Regulatory Framework
      • 9.6.3.6 Reimbursement Scenario
    • 9.6.4 UAE
      • 9.6.4.1 Key Country Dynamics
      • 9.6.4.2 Target Disease Prevalence
      • 9.6.4.3 Uae Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.6.4.4 Competitive Scenario
      • 9.6.4.5 Regulatory Framework
      • 9.6.4.6 Reimbursement Scenario
    • 9.6.5 Kuwait
      • 9.6.5.1 Key Country Dynamics
      • 9.6.5.2 Target Disease Prevalence
      • 9.6.5.3 Kuwait Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.6.5.4 Competitive Scenario
      • 9.6.5.5 Regulatory Framework
      • 9.6.5.6 Reimbursement Scenario
    • 9.6.6 Rest Of Mea

Chapter 10 Competitive Landscape

  • 10.1 Company Categorization
  • 10.2 Strategy Mapping
    • 10.2.1 New Product Launch
    • 10.2.2 Partnerships
    • 10.2.3 Acquisition
    • 10.2.4 Collaboration
    • 10.2.5 Funding
  • 10.3 Key Company Market Share Analysis, 2022
  • 10.4 Company Profiles
    • 10.4.1 Thermo Fisher Scientific, Inc.
      • 10.4.1.1 Company Overview
      • 10.4.1.2 Financial Performance
      • 10.4.1.3 Product Benchmarking
      • 10.4.1.4 Strategic Initiatives
    • 10.4.2 F. Hoffmann-La Roche Ltd.
      • 10.4.2.1 Company Overview
      • 10.4.2.2 Financial Performance
      • 10.4.2.3 Product Benchmarking
      • 10.4.2.4 Strategic Initiatives
    • 10.4.3 Siemens Healthineers
      • 10.4.3.1 Company Overview
      • 10.4.3.2 Financial Performance
      • 10.4.3.3 Product Benchmarking
      • 10.4.3.4 Strategic Initiatives
    • 10.4.4 Abbott
      • 10.4.4.1 Company Overview
      • 10.4.4.2 Financial Performance
      • 10.4.4.3 Product Benchmarking
      • 10.4.4.4 Strategic Initiatives
    • 10.4.5 BioMerieux SA
      • 10.4.5.1 Company Overview
      • 10.4.5.2 Financial Performance
      • 10.4.5.3 Product Benchmarking
      • 10.4.5.4 Strategic Initiative
    • 10.4.6 Werfen
      • 10.4.6.1 Company Overview
      • 10.4.6.2 Financial Performance
      • 10.4.6.3 Product Benchmarking
      • 10.4.6.4 Strategic Initiatives
    • 10.4.7 HORIBA Ltd.
      • 10.4.7.1 Company Overview
      • 10.4.7.2 Financial Performance
      • 10.4.7.3 Product Benchmarking
      • 10.4.7.4 Strategic Initiatives
    • 10.4.8 Quidel Corporation
      • 10.4.8.1 Company Overview
      • 10.4.8.2 Financial Performance
      • 10.4.8.3 Product Benchmarking
      • 10.4.8.4 Strategic Initiatives
    • 10.4.9 Diazyme Laboratories, Inc.
      • 10.4.9.1 Company Overview
      • 10.4.9.2 Financial Performance
      • 10.4.9.3 Product Benchmarking
      • 10.4.9.4 Strategic Initiatives
    • 10.4.10 Biomedica Diagnostics
      • 10.4.10.1 Company Overview
      • 10.4.10.2 Financial Performance
      • 10.4.10.3 Product Benchmarking
      • 10.4.10.4 Strategic Initiatives

Chapter 11 Conclusion

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 4 Global thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 5 Global thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 6 Global thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 7 Global thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 8 Global thrombosis & hemostasis biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 9 North America thrombosis & hemostasis biomarkers market, by country, 2018 - 2030 (USD Million)
  • Table 10 North America thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 11 North America thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 12 North America thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 13 North America thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 14 North America thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 15 U.S. thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 16 U.S. thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 17 U.S. thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 18 U.S. thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 19 U.S. thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 20 Canada thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 21 Canada thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 22 Canada thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 23 Canada thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 24 Canada thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 25 Europe thrombosis & hemostasis biomarkers market, by country, 2018 - 2030 (USD Million)
  • Table 26 Europe thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 27 Europe thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 28 Europe thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 29 Europe thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 30 Europe thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 31 Germany thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 32 Germany thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 33 Germany thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 34 Germany thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 35 Germany thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 36 UK thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 37 UK thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 38 UK thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 39 UK thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 40 UK thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 41 France thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 42 France thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 43 France thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 44 France thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 45 France thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 46 Italy thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 47 Italy thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 48 Italy thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 49 Italy thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 50 Italy thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 51 Spain thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 52 Spain thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 53 Spain thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 54 Spain thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 55 Spain thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 56 Denmark thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 57 Denmark thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 58 Denmark thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 59 Denmark thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 60 Denmark thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 61 Sweden thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 62 Sweden thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 63 Sweden thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 64 Sweden thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 65 Sweden thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 66 Norway thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 67 Norway thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 68 Norway thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 69 Norway thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 70 Norway thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 71 Asia Pacific thrombosis & hemostasis biomarkers market, by country, 2018 - 2030 (USD Million)
  • Table 72 Asia Pacific thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 73 Asia Pacific thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 74 Asia Pacific thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 75 Asia Pacific thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 76 Asia Pacific thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 77 China thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 78 China thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 79 China thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 80 China thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 81 China thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 82 Japan thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 83 Japan thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 84 Japan thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 85 Japan thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 86 Japan thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 87 India thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 88 India thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 89 India thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 90 India thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 91 India thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 92 South Korea thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 93 South Korea thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 94 South Korea thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 95 South Korea thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 96 South Korea thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 97 Australia thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 98 Australia thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 99 Australia thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 100 Australia thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 101 Australia thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 102 Thailand thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 103 Thailand thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 104 Thailand thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 105 Thailand thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 106 Thailand thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 107 Latin America thrombosis & hemostasis biomarkers market, by country, 2018 - 2030 (USD Million)
  • Table 108 Latin America thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 109 Latin America thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 110 Latin America thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 111 Latin America thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 112 Latin America thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 113 Brazil thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 114 Brazil thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 115 Brazil thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 116 Brazil thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 117 Brazil thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 118 Mexico thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 119 Mexico thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 120 Mexico thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 121 Mexico thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 122 Mexico thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 123 Argentina thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 124 Argentina thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 125 Argentina thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 126 Argentina thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 127 Argentina thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 128 Middle East & Africa thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 129 Middle East & Africa thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 130 Middle East & Africa thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 131 Middle East & Africa thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 132 Middle East & Africa thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 133 South Africa thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 134 South Africa thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 135 South Africa thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 136 South Africa thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 137 South Africa thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 138 Saudi Arabia thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 139 Saudi Arabia thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 140 Saudi Arabia thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 141 Saudi Arabia thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 142 Saudi Arabia thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 143 UAE thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 144 UAE thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 145 UAE thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 146 UAE thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 147 UAE thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 148 Kuwait thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 149 Kuwait thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 150 Kuwait thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 151 Kuwait thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 152 Kuwait thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Thrombosis & hemostasis biomarkers market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Product and test location segment snapshot
  • Fig. 11 Test type segment snapshot
  • Fig. 12 Application and end-use segment snapshot
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 IVD market value, 2022 (USD Million)
  • Fig. 15 Market dynamics
  • Fig. 16 Incidence of global pancreatic cancer, 2017 - 2021
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTLE analysis
  • Fig. 19 Thrombosis & hemostasis biomarkers market: Product outlook and key takeaways
  • Fig. 20 Thrombosis & hemostasis biomarkers market: Product movement analysis
  • Fig. 21 Analyzers Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Reagents & consumables market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Thrombosis & hemostasis biomarkers market: Test location outlook and key takeaways
  • Fig. 24 Thrombosis & hemostasis biomarkers market: Test location movement analysis
  • Fig. 25 Clinical laboratory tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Point-of-care tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Thrombosis & hemostasis biomarkers market: Test type outlook and key takeaways
  • Fig. 28 Thrombosis & hemostasis biomarkers market: Test type movement analysis
  • Fig. 29 D- dimer test market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Anti-thrombin III market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Plasminogen market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Fibrin/Fibrinogen Market Estimates and Forecast, 2018-2030, USD Million
  • Fig. 33 Soluble fibrin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Selectins Market Estimates and Forecast, 2018-2030, USD Million
  • Fig. 35 Factor VIII market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 PT market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 APTT Market Estimates and Forecast, 2018-2030, USD Million
  • Fig. 38 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Thrombosis & hemostasis biomarkers market: Application outlook and key takeaways
  • Fig. 40 Thrombosis & hemostasis biomarkers market: Application movement analysis
  • Fig. 41 Deep Vein Thrombosis (DVT) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Pulmonary Embolism (PE) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Disseminated Intravascular Coagulation (DIC) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 Thrombosis & hemostasis biomarkers market: End-use outlook and key takeaways
  • Fig. 46 Thrombosis & hemostasis biomarkers market: End-use movement analysis
  • Fig. 47 Hospitals & clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Academic & research institute market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Diagnostic centers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Thrombosis & hemostasis biomarkers market revenue, by region, 2022 & 2030, (USD Million)
  • Fig. 52 Regional marketplace: Key takeaways
  • Fig. 53 Regional marketplace: Key takeaways
  • Fig. 54 North America thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 U.S. thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Canada thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Europe thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 UK thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 Germany thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 France thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 Spain thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Italy thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Denmark thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Sweden thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Norway thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Rest of Europe thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD, Million)
  • Fig. 77 Asia Pacific thrombosis & hemostasis biomarkers market estimates and forecast, 2018 - 2030, (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 Japan thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 China thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 India thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 South Korea thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 South Korea reimbursement scenario
  • Fig. 87 Key country dynamics
  • Fig. 88 Australia thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Key country dynamics
  • Fig. 90 Thailand thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Rest of Asia Pacific thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Latin America thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Key country dynamics
  • Fig. 94 Brazil thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Key country dynamics
  • Fig. 96 Mexico thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Key country dynamics
  • Fig. 98 Argentina thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Rest of Latin America thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 100 MEA thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 Key country dynamics
  • Fig. 102 South Africa thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Key country dynamics
  • Fig. 104 Saudi Arabia thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 Key country dynamics
  • Fig. 106 UAE thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 107 Key country dynamics
  • Fig. 108 Kuwait thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 Rest of MEA thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 110 Key company categorization
  • Fig. 111 Company categorization
  • Fig. 112 Company market share analysis, 2022
  • Fig. 113 North America - company market share analysis, 2022
  • Fig. 114 Europe- company market share analysis, 2022
  • Fig. 115 Asia Pacific- company market share analysis, 2022
  • Fig. 116 Latin America- company market share analysis, 2022
  • Fig. 117 MEA- company market share analysis, 2022
  • Fig. 118 Strategic framework